6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.

Probably not a substantial claim: may not pass S3 (load-bearing).

Nevertheless, epidemiologic studies reveal a substantial burden of hypoglycemia-related hospital utilization in the community.

“Nevertheless, they reveal a substantial burden of hypoglycemia-related hospital utilization in the community (87)(88)(89)(90).”

• cites [87] Karter, 2018, Surveillance of hypoglycemia-limitations of emergency department and hospital utilization data, JAMA Intern Med sourceDisputed

  The Discussion describes hypoglycemia-related ED visits or hospitalization as rare, at approximately 0.8% annually, rather than a substantial burden of hospital utilization. The Results report documented ED or hospital utilization for 102 of 13,359 patients; the paper emphasizes that utilization data miss most severe hypoglycemic events. (LLM, conf=0.85)

  Checked by a reasoning model — may be wrong.

  Experimental — accuracy not yet measured
• cites [88] Lee, 2017, Risk factors for severe hypoglycemia in black and white adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) study, Diabetes Care sourceSupported
• cites [89] Pilla, 2021, Hospital utilization for hypoglycemia among patients with type 2 diabetes using pooled data from six health systems, BMJ Open Diabetes Res Care sourceSupported
• cites [90] McCoy, 2023, Rates of hypoglycemic and hyperglycemic emergencies among U.S. adults with diabetes, 2011–2020, Diabetes Care sourceSupported

May combine two claims.

Point-of-care A1C testing can offer timely opportunities for treatment adjustments during appointments with health care professionals, although point-of-care tests may be less accurate than laboratory A1C assays.

“Point-of-care A1C testing can offer timely opportunities for treatment adjustments during appointments with health care professionals, although point-of-care tests may be less accurate than laboratory A1C assays (5).”

• cites [5] Sacks, 2024, Point-of-care HbA1c in clinical practice: caveats and considerations for optimal use, Diabetes Care sourceSupported

May combine two claims.

The A1C test is the primary tool for assessing glycemic status in both clinical practice and clinical trials, and it is strongly linked to diabetes complications.

“The A1C test is the primary tool for assessing glycemic status in both clinical practice and clinical trials, and it is strongly linked to diabetes complications (2)(3)(4).”

• cites [2] Laiteerapong, 2019, The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study), Diabetes Care sourcePartly supported

  The Conclusions report that higher early HbA1c levels were associated with greater risk of diabetic complications in patients newly diagnosed with type 2 diabetes who survived at least 10 years. The Exposure methods use HbA1c to assess glycemic control, and the Introduction discusses trials that used it, but neither establishes that the A1C test is the primary assessment tool in both clinical practice and clinical trials. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [3] Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ sourceNot checked — no full text of the source
• cites [4] Little, 2011, Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care, Clin Chem sourceNot checked — no full text of the source

May combine two claims.

Standardized reports with visual summaries have been implemented and help individuals with diabetes and health care professionals interpret the data to guide treatment decisions.

“To make these metrics actionable, standardized reports with visual summaries have been implemented (33) and help individuals with diabetes and health care professionals interpret the data to guide treatment decisions (27,30).”

• cites [33] Battelino, 2019, Clinical targets for continuous glucose monitoring data interpretation: recommendations from the International Consensus on Time in Range, Diabetes Care sourceSupported
• cites [27] Advani, 2020, Positioning time in range in diabetes management, Diabetologia sourceSupported
• cites [30] Kröger, 2020, Clinical recommendations for the use of the ambulatory glucose profile in diabetes care, J Diabetes Sci Technol sourceNot checked — no full text of the source

May combine two claims.

CGM is particularly useful in people with diabetes who are at risk for hypoglycemia and in people with type 1 diabetes.

“CGM is particularly useful in people with diabetes who are at risk for hypoglycemia and in people with type 1 diabetes (21).”

• cites [21] Holt, 2021, The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care sourcePartly supported

  The Continuous Glucose Monitoring section says CGM is standard for most adults with type 1 diabetes and that real-time CGM reduces hypoglycemia, including in older adults and those with impaired awareness of hypoglycemia. The report addresses adults with type 1 diabetes; it does not establish the broader claim for all people with diabetes who are at risk of hypoglycemia. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

A 10- to 14-day CGM assessment of TIR, with CGM wear of 70% or higher, and other CGM metrics can be used to assess glycemic status and are useful in clinical management.

“A 10-to 14-day CGM assessment of TIR, with CGM wear of 70% or higher, and other CGM metrics can be used to assess glycemic status and are useful in clinical management (22)(23)(24)(25)(26).”

• cites [22] Valenzano, 2021, Time in range-A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study, BMJ Open Diabetes Res Care sourcePartly supported

  The Introduction says TIR and other CGM metrics can aid glucose control, and the Methods say 14 days of CGM data are often considered a good estimate of metrics over three months. But the paper does not establish the claimed 10-to-14-day assessment with at least 70% wear: it excluded periods with less than 70% wear and calculated TIR from 90-day periods, not 10-to-14-day periods (Data collection and statistical analysis; page unavailable). (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [23] Fabris, 2020, Estimation of hemoglobin A1c from continuous glucose monitoring data in individuals with type 1 diabetes: is time in range all we need?, Diabetes Technol Ther sourcePartly supported

  The Discussion describes TIR and other CGM metrics as useful for assessing glycemic control and managing type 1 diabetes. It does not establish a 70% CGM-wear threshold or endorse a 10- to 14-day assessment; instead, it says 2 to 3 weeks of CGM data appear sufficient to calibrate this paper’s HbA1c-estimation model. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [24] Ranjan, 2020, Improved time in range over 1 year is associated with reduced albuminuria in individuals with sensor-augmented insulin pump-treated type 1 diabetes, Diabetes Care sourceNot checked — no full text of the source

May combine two claims.

The benefit of intensive glycemic management in the EDIC cohort of people with type 1 diabetes has been shown to persist for 30 years and was associated with a 32% reduction in cardiovascular disease events.

“The benefit of intensive glycemic management in the EDIC cohort of people with type 1 diabetes has been shown to persist for 30 years and was associated with a 32% reduction in CVD events (59).”

• cites [59] Nathan, 2009, Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications Experience (1983–2005), Arch Intern Med sourcePartly supported

  The Results—Long-Term Complications section (page unavailable) reports a lasting benefit after 30 years of diabetes: CVD incidence was 9% in the original intensive-treatment group versus 14% in the conventional-treatment group. That is approximately a 36% relative reduction, not the claimed 32%. The 30 years refers to diabetes duration, not 30 years of EDIC follow-up. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Post-trial observational follow-up of the VADT over 10 years has also shown a significant reduction in the primary outcome of major cardiovascular disease events, with myocardial infarctions and heart failure being the most common outcomes.

“Post-trial observational follow-up of the VADT over 10 years has also shown a significant reduction in the primary outcome of major CVD events, with myocardial infarctions and heart failure being the most common outcomes (60).”

• cites [60] Hayward, 2015, Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes, N Engl J Med sourcePartly supported

  The Primary Outcome and Secondary Outcomes section reports a significant reduction in major cardiovascular events after a median 9.8 years of follow-up (hazard ratio 0.83; P=0.04). The Primary and Secondary Outcomes section includes heart attacks and new or worsening heart failure in the composite, but our copy does not establish that they were the most common outcomes; it directs readers to supplementary tables for component results. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

May combine two claims.

Subsequent cardiovascular and kidney outcomes trials of these agents were not designed to test higher versus lower A1C; therefore, beyond limited post hoc analysis of these trials, there is limited evidence of the independent cardiovascular and kidney effects of glucose lowering when conferred by these medication classes.

“Subsequent cardiovascular and kidney outcomes trials of these agents were not designed to test higher versus lower A1C; therefore, beyond limited post hoc analysis of these trials, there is limited evidence of the independent cardiovascular and kidney effects of glucose lowering when conferred by these medication classes (63).”

• cites [63] Buse, 2020, Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial, Diabetes Care sourcePartly supported

  Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

  Experimental — accuracy not yet measured

May combine two claims.

The ADVANCE and VADT trials found modest reduction in nephropathy with intensive glycemic management; ACCORD was stopped after a median of 3.5 years due to higher mortality in the intervention arm.

“The ADVANCE and VADT trials found modest reduction in nephropathy with intensive glycemic management; ACCORD was stopped after a median of 3.5 years due to higher mortality in the intervention arm (51-55).”

• cites [51] Duckworth, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med sourcePartly supported

  The Discussion reports reduced progression of albuminuria in both ADVANCE and VADT, and says ACCORD was stopped after 3.5 years because mortality was higher with intensive therapy. The nephropathy claim is broader than the findings: the paper reports no reduction in severe or major nephropathy. It also does not identify 3.5 years as ACCORD’s median follow-up. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [52] Patel, 2008, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med sourcePartly supported

  The Discussion (p. 11) reports a 21% relative reduction in new or worsening nephropathy in ADVANCE. The Discussion (p. 12) also reports that excess mortality led to premature termination of ACCORD’s intensive glucose-control strategy. Our copy does not establish a nephropathy reduction in VADT or the claimed median of 3.5 years for ACCORD. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [53] Ismail-Beigi, 2010, Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial, Lancet sourcePartly supported

  The Discussion reports that ADVANCE and VADT found reductions in microalbuminuria with intensive glycemic treatment, supporting the renal-outcome point at that narrower level. The Introduction says ACCORD’s intensive strategy was stopped because of increased all-cause mortality, but gives a median follow-up of 3.7 years, not 3.5 years. Page numbers are unavailable in our copy. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [54] Gerstein, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source
• cites [55] Agrawal, 2019, Intensive glycemic control improves long-term renal outcomes in type 2 diabetes in the Veterans Affairs Diabetes Trial (VADT), Diabetes Care sourcePartly supported

  The VADT results section (page not provided) reports a 19% reduction in a composite renal outcome with intensive glycemic control at 15 years, supporting the VADT portion of the sentence. The paper does not report the ADVANCE nephropathy finding or the claim that ACCORD was stopped after a median of 3.5 years because of higher mortality. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Individuals at risk for hypoglycemia are those treated with insulin, sulfonylureas, or meglitinides; clinically significant hypoglycemia is rare among individuals taking other diabetes medication classes.

“Individuals at risk for hypoglycemia are those treated with insulin, sulfonylureas, or meglitinides; clinically significant hypoglycemia is rare among individuals taking other diabetes medication classes (94,95).”

• cites [94] Silbert, 2018, Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies, Curr Diab Rep sourceSupported
• cites [95] McCoy, 2020, Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes, JAMA Netw Open sourcePartly supported

  The Results (Crude Rates of Hypoglycemia-Related ED Visits and Hospitalizations; page not provided) report much higher rates among patients taking sulfonylureas or insulin than among those taking other medications. But the Methods (Independent Variables; page not provided) group meglitinides with those other medications, so this paper does not establish their risk separately. Its outcome is hypoglycemia requiring an ED visit or hospitalization, rather than all clinically significant hypoglycemia. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Level 3 hypoglycemia may be recognized or unrecognized and can progress to loss of consciousness, seizure, coma, or death.

“Level 3 hypoglycemia may be recognized or unrecognized and can progress to loss of consciousness, seizure, coma, or death.”

• cites [75] Sreenan, 2014, Increased risk of severe hypoglycemic events with increasing frequency of non-severe hypoglycemic events in patients with type 1 and type 2 diabetes, Diabetes Ther sourcePartly supported

  The Methods section (Hypoglycemic Events; page unavailable) defines severe hypoglycemic events as episodes requiring third-party assistance, which supports the claim’s characterization of severe hypoglycemia. Our copy does not use the term “Level 3” or state that such events may be recognized or unrecognized or progress to loss of consciousness, seizure, coma, or death. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Individuals may tolerate hypoglycemia without treatment either because of lack of symptoms or to avoid hyperglycemia.

“It is essential to correlate glucose readings, both from glucose meters and CGM systems, with symptoms and treatment, as individuals may experience and treat hypoglycemic symptoms without checking their glucose level (107), treat normal glucose values as hypoglycemic, or tolerate hypoglycemia without treatment either because of lack of symptoms or to avoid hyperglycemia.”

• cites [107] Pilla, 2021, Hypoglycemia communication in primary care visits for patients with diabetes, J Gen Intern Med sourcePartly supported

  The Introduction (page not provided) describes hypoglycemia unawareness: a person may have low blood glucose without autonomic symptoms. The paper does not say that people leave hypoglycemia untreated because they lack symptoms or because they want to avoid hyperglycemia. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

Level 3 hypoglycemia was associated with mortality in both the standard and the intensive glycemia arms of the ACCORD trial, but the relationships between hypoglycemia, achieved A1C, and treatment intensity were not straightforward.

“Level 3 hypoglycemia was associated with mortality in both the standard and the intensive glycemia arms of the ACCORD trial, but the relationships between hypoglycemia, achieved A1C, and treatment intensity were not straightforward (76).”

• cites [76] Bonds, 2010, The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study, BMJ sourcePartly supported

  The Abstract reports that symptomatic, severe hypoglycaemia was associated with increased mortality within both ACCORD treatment arms. The Results and Study strengths and limitations sections show that the association differed by treatment arm and that treatment strategies complicate its interpretation. The passages discuss A1C targets, however, not the relationship with achieved A1C specifically; page numbers were not available in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

May combine two claims.

These studies do not capture the level 1 and level 2 hypoglycemia that represent the vast majority of hypoglycemic events, and they also substantially underestimate level 3 hypoglycemia.

“These studies do not capture the level 1 and level 2 hypoglycemia that represent the vast majority of hypoglycemic events, and they also substantially underestimate level 3 hypoglycemia (87,91,92).”

• cites [87] Karter, 2018, Surveillance of hypoglycemia-limitations of emergency department and hospital utilization data, JAMA Intern Med sourcePartly supported

  The Discussion reports that ED and hospital surveillance captures only about 5% of self-reported severe hypoglycemic events among pharmacologically treated patients with diabetes, supporting substantial underestimation of level 3 events. The paper does not assess level 1 or level 2 events or establish that they constitute the vast majority of all hypoglycemic events. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [91] Mattishent, 2018, Detection of asymptomatic drug-induced hypoglycemia using continuous glucose monitoring in older people - Systematic review, J Diabetes Complications sourcePartly supported

  The Evidence Synthesis (§3.2; page unavailable) reports that 80–100% of hypoglycemic events in the reviewed studies were asymptomatic and likely would have gone unnoticed without continuous glucose monitoring. This supports the point that many events are missed, but the paper does not establish that missed events were specifically level 1 or level 2, or that level 3 hypoglycemia was substantially underestimated. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [92] Ratzki-Leewing, 2023, Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States), Diabetes Obes Metab sourcePartly supported

  The Introduction says claims- and records-based surveillance misses 90%–95% of level 3 events treated outside the health care system, and the Discussion reports that three-quarters of level 3 events were treated outside that system. This supports substantial underestimation of level 3 hypoglycaemia. The paper does not establish that level 1 and 2 events make up the vast majority of all hypoglycaemic events or explicitly assess whether these studies capture them. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Individualized glycemic goals, education, nutrition intervention, physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve outcomes.

“Individualized glycemic goals, education, nutrition intervention, physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve outcomes (108).”

• cites [108] Seaquist, 2013, Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society, Diabetes Care sourceSupported

May combine two claims.

Dietary protein intake may increase insulin secretion and should not be used to treat hypoglycemia.

“Dietary protein intake may increase insulin secretion and should not be used to treat hypoglycemia (136).”

• cites [136] Layman, 2008, Protein in optimal health: heart disease and type 2 diabetes, Am J Clin Nutr sourcePartly supported

  The section “Protein Intake, Glucose Homeostasis, and Type 2 Diabetes” (pp. 1–4) says dietary protein can stimulate insulin release, particularly in people with type 2 diabetes. It does not address whether protein should be used to treat hypoglycemia (searched: hypoglycemia, treating low blood glucose), so the treatment recommendation is unsupported. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

CGM can reveal asymptomatic hypoglycemia and help identify patterns and precipitants of hypoglycemic events and provide alarms that can warn individuals of falling glucose so that they can intervene.

“CGM can reveal asymptomatic hypoglycemia and help identify patterns and precipitants of hypoglycemic events and provide alarms that can warn individuals of falling glucose so that they can intervene (150,151).”

• cites [150] Heinemann, 2018, Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial, Lancet sourceNot checked — no full text of the source
• cites [151] Hermanns, 2019, Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study, J Diabetes Sci Technol sourcePartly supported

  The ‘Can CGM Facilitate Diagnosis of Hypoglycemia Problems?’ section says CGM detects previously unrecognized asymptomatic episodes, and ‘Is rtCGM an Effective Intervention to Reduce Hypoglycemia Problems?’ describes alerts and glucose trends that allow an immediate response. The paper also describes glucose histories that can reveal patterns, but the passages do not establish that CGM identifies the precipitants of individual hypoglycemic events. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

May combine two claims.

CGM may also be helpful to reduce hypoglycemia and improve quality of life in people with hypoglycemia as a complication of metabolic surgery.

“CGM may also be helpful to reduce hypoglycemia and improve quality of life in people with hypoglycemia as a complication of metabolic surgery (152,153).”

• cites [152] Cummings, 2023, Continuous glucose monitoring in patients with post-bariatric hypoglycaemia reduces hypoglycaemia and glycaemic variability, Diabetes Obes Metab sourcePartly supported

  The Discussion reports that CGM reduced hypoglycaemia in patients with post-bariatric hypoglycaemia. It also says that further studies are needed to determine its impact on quality of life in these patients, so the quality-of-life part is not established by this paper. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [153] Turk, 2025, Continuous glucose monitoring in patients with postbariatric hypoglycemia: effect on hypoglycemia and quality of life, J Endocr Soc sourceSupported

May combine two claims.

Female sex has also been found to be an independent risk factor for hypoglycemia in multiple studies, although the mechanisms of this relationship are unclear and require further research.

“Female sex has also been found to be an independent risk factor for hypoglycemia in multiple studies, although the mechanisms of this relationship are unclear and require further research (94).”

• cites [94] Silbert, 2018, Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies, Curr Diab Rep sourceCould not verify

  The Risk Factors for Hypoglycemia section discusses age, treatment, comorbidities and social determinants, but does not identify female sex as an independent risk factor. Searches for female sex, women, and sex as an independent predictor found no passage addressing the claimed association or its mechanisms. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

May combine two claims.

Individuals with low annual household incomes, individuals who live in socioeconomically deprived areas, and individuals who are underinsured or experiencing housing instability experience higher rates of emergency department visits and hospitalizations for hypoglycemia.

“In general, individuals with low annual household incomes (95), individuals who live in socioeconomically deprived areas (98), and individuals who are underinsured (99) or experiencing housing instability (122) experience higher rates of emergency department visits and hospitalizations for hypoglycemia.”

• cites [95] McCoy, 2020, Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes, JAMA Netw Open sourceSupported
• cites [98] Kurani, 2022, Association of area-level socioeconomic deprivation with hypoglycemic and hyperglycemic crises in US adults with diabetes, JAMA Netw Open sourceSupported
• cites [99] Jiang, 2023, Evaluation of high-deductible health plans and acute glycemic complications among adults with diabetes, JAMA Netw Open sourcePartly supported

  The Introduction identifies high-deductible health plans (HDHPs) as a setting of underinsurance. The Results (Severe Hypoglycemia After Switching to an HDHP; page unavailable) report that each year of HDHP enrollment increased the odds of a hypoglycemia-related emergency department visit or hospitalization by 2% among adults with diabetes. This supports the underinsurance portion of the citing sentence for HDHP enrollees, but does not establish higher rates for underinsured people generally; switching to an HDHP did not increase those odds over the whole observation period. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [122] Sharan, 2023, The association of homelessness with rates of diabetes complications: a population-based cohort study, Diabetes Care sourceSupported

May combine two claims.

Intranasal and ready-to-inject glucagon preparations are now widely available and are preferred due to their ease of administration resulting in more rapid correction of hypoglycemia.

“However, intranasal and ready-to-inject glucagon preparations are now widely available and are preferred due to their ease of administration resulting in more rapid correction of hypoglycemia (143-145).”

• cites [143] Matsuhisa, 2020, Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: a phase 3 randomized crossover study, Diabetes Obes Metab sourcePartly supported

  The Introduction (page unavailable) describes nasal glucagon as ready to use and easier to administer than injectable glucagon. But the Results and Discussion (page unavailable) report that correction was one minute faster with intramuscular glucagon after administration; the authors suggest preparation time would offset that difference in practice. The paper does not establish that nasal and ready-to-inject preparations are widely available or preferred, and it does not evaluate a ready-to-inject preparation. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [144] Suico, 2020, Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: a randomised, open-label, crossover study, Diabetes Ther sourcePartly supported

  The Introduction and Discussion support nasal glucagon’s ease of administration compared with a reconstituted injection. But the Results report faster treatment success after intramuscular glucagon (9.9 versus 11.4 minutes), while noting that this comparison excluded injection preparation time. The paper does not establish that nasal and ready-to-inject products are widely available or preferred, or that they produce more rapid correction overall. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [145] Pieber, 2022, Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes, Diabetes Obes Metab sourceNot checked — no full text of the source

May combine two claims.

Other notable clinical and biological risk factors for hypoglycemia are very young age, older age, multimorbidity, cognitive impairment, chronic kidney disease and kidney failure, CVD, depression, neuropathy, and gastroparesis.

“Other notable clinical and biological risk factors for hypoglycemia are very young age, older age, multimorbidity, cognitive impairment, chronic kidney disease and kidney failure, CVD, depression, neuropathy, and gastroparesis (94,95,117).”

• cites [94] Silbert, 2018, Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies, Curr Diab Rep sourcePartly supported

  The Risk Factors for Hypoglycemia section identifies older age, multimorbidity, kidney disease, cognitive impairment, cardiovascular disease, and depression as risk factors; the Preventing Hypoglycemia section also identifies advanced kidney disease as a high-risk condition. Our copy does not identify very young age, neuropathy, or gastroparesis as risk factors. Page numbers are unavailable in the indexed copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [95] McCoy, 2020, Association of cumulative multimorbidity, glycemic control, and medication use with hypoglycemia-related emergency department visits and hospitalizations among adults with diabetes, JAMA Netw Open sourcePartly supported

  The Results (Independent Risk Factors for Hypoglycemia-Related ED Visits and Hospitalizations; page unavailable) support older age (75 or above), multimorbidity, kidney disease or failure, myocardial infarction, cerebrovascular disease, depression, and peripheral neuropathy as risk factors for hypoglycemia-related emergency care. The paper studied adults, so it does not support very young age; it found dementia was not independently associated with this outcome and does not address gastroparesis. Its cardiovascular findings also do not extend to every form of CVD: heart failure was not independently associated. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [117] Homko, 2016, The impact of gastroparesis on diabetes control: patient perceptions, J Diabetes Complications sourceNot checked — no full text of the source

May combine two claims.

Structured diabetes self-management education and support that includes problem-solving is effective at reducing DKA admissions, as are psychological interventions, peer support, individual coaching, and behavioral family systems therapy.

“Structured diabetes self-management education and support that includes problem-solving is effective at reducing DKA admissions, as are psychological interventions, peer support, individual coaching, and behavioral family systems therapy (183,184).”

• cites [183] Ehrmann, 2020, Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes, Lancet Diabetes Endocrinol sourceNot checked — no full text of the source
• cites [184] Elliott, 2014, Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with type 1 diabetes, Diabet Med sourcePartly supported

  The Results report fewer hospital-admitted DKA episodes after DAFNE structured education in adults with type 1 diabetes, and the Discussion concludes that admissions fell after the training. The copy does not establish that problem-solving was a component of DAFNE. Although the Discussion mentions a separate finding for intensive home-based family therapy in adolescents, it does not support the broader list of psychological interventions, peer support, individual coaching, and behavioral family systems therapy. Page numbers were not available in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Several evidence-based training programs have been developed for this purpose and have been demonstrated to reduce rates of hypoglycemia and improve quality of life among people with type 1 diabetes and impaired hypoglycemia awareness.

“Several evidence-based training programs have been developed for this purpose and have been demonstrated to reduce rates of hypoglycemia and improve quality of life among people with type 1 diabetes and impaired hypoglycemia awareness (74,155,156).”

• cites [74] Amiel, 2022, A parallel randomised controlled trial of the Hypoglycaemia Awareness Restoration Programme for adults with type 1 diabetes and problematic hypoglycaemia despite optimised self-care (HARPdoc), Nat Commun sourcePartly supported

  The Results (Primary outcome) report lower severe-hypoglycaemia rates after the HARPdoc and BGAT training programmes in adults with type 1 diabetes and impaired awareness. The Results (Secondary endpoints) also report lower diabetes-distress, anxiety and depression scores with HARPdoc than with BGAT, but the paper does not establish improved quality of life for the training programmes generally; it describes the emotional-outcome findings as exploratory. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [155] Cox, 2001, Blood glucose awareness training (BGAT-2): long-term benefits, Diabetes Care sourceNot checked — no full text of the source
• cites [156] Little, 2018, Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: two-year follow-up in the HypoCOMPaSS randomized clinical trial, Diabetes Care sourceNot checked — no full text of the source

May combine two claims.

Other factors associated with DKA include age 10-14 years, public insurance, and prior episodes of DKA.

“Other factors associated with DKA include age 10-14 years, public insurance, and prior episodes of DKA; use of insulin pump therapy does not appear to be associated with increased DKA occurrence in the current era.”

• cites [186] Garvey, 2022, Health care utilization trends across the transition period in a national cohort of adolescents and young adults with type 1 diabetes, Diabetes Care sourceCould not verify

  The Methods/Abstract describe a cohort aged 16–24, and the Conclusions state that publicly insured populations were not included. Our copy does not address whether age 10–14, public insurance, or prior DKA episodes are associated with DKA (searched those terms and variants). (LLM, conf=0.76)

  Experimental — accuracy not yet measured
• cites [187] Fritsch, 2011, Predictors of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Experience from a large multicentre database, Pediatr Diabetes sourcePartly supported

  The Results report higher DKA rates for children aged 11–15 at diabetes onset, broadly supporting the age association but not the stated 10–14-year range. The Discussion mentions underinsurance in previous studies, not public insurance, and the Results count recurrent DKA episodes without establishing prior episodes as a predictor of later DKA. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [188] Schwartz, 2025, Severe and recurrent diabetic ketoacidosis in children and youth with type 1 diabetes: risk and protective factors, Diabetes Technol Ther sourceNot checked — no full text of the source

May combine two claims.

DKA is often associated with psychosocial challenges, such as disordered eating behaviors, and with periods of transition, such as from pediatric to adult health care when there may be gaps in ambulatory care.

“Notably, the majority of DKA cases occur in those with established diabetes compared with those with newly diagnosed diabetes, often in association with psychosocial challenges, such as disordered eating behaviors, and during periods of transition, such as from pediatric to adult health care when there may be gaps in ambulatory care (186)(187)(188).”

• cites [186] Garvey, 2022, Health care utilization trends across the transition period in a national cohort of adolescents and young adults with type 1 diabetes, Diabetes Care sourcePartly supported

  The Abstract describes gaps between pediatric and adult diabetes care and identifies DKA as a risk for young adults with type 1 diabetes. The Conclusions link irregular endocrinology follow-up with DKA admission. Our copy does not link DKA to psychosocial challenges or disordered eating behaviors. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [187] Fritsch, 2011, Predictors of diabetic ketoacidosis in children and adolescents with type 1 diabetes. Experience from a large multicentre database, Pediatr Diabetes sourcePartly supported

  The paper’s introductory passage says most DKA cases occur in patients with previously diagnosed diabetes, and the Discussion links disordered eating and bulimic symptoms to increased DKA risk. The passages do not address transition from pediatric to adult care or gaps in ambulatory care; a search for those terms found no support for that part of the sentence. Page numbers were not available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [188] Schwartz, 2025, Severe and recurrent diabetic ketoacidosis in children and youth with type 1 diabetes: risk and protective factors, Diabetes Technol Ther sourceNot checked — no full text of the source

May combine two claims. The quote only partly states this claim.

Risk factors for hyperglycemic crises include younger age, prior history of hyperglycemic crises, prior history of hypoglycemic crises, presence of other diabetes complications, presence of other chronic health conditions, presence of behavioral health conditions, alcohol and/or substance use, high A1C level, insulin rationing, SGLT2 inhibitor use, and social determinants of health.

“There are a number of clinical factors associated with an increased risk of hyperglycemic crises (Table 6.8).”

• Also stated in: § References · plain

  “Type 1 diabetes/absolute insulin deficiency Younger age Prior history of hyperglycemic crises Prior history of hypoglycemic crises Presence of other diabetes complications Presence of other chronic health conditions (particularly in people with type 2 diabetes) Presence of behavioral health conditions (e.g., depression, bipolar disorder, and eating disorders) Alcohol and/or substance use High A1C”

• cites [194] McCoy, 2021, Sociodemographic, clinical, and treatment-related factors associated with hyperglycemic crises among adults with type 1 or type 2 diabetes in the US from 2014 to 2020, JAMA Netw Open sourcePartly supported

  The Results (Factors Associated With Hyperglycemic Crises; page unavailable) support younger age, prior crises and severe hypoglycemia, several diabetes complications and chronic conditions, depression, high HbA1c, SGLT2 inhibitor use, and low income. The Discussion (page unavailable) describes insulin rationing as a possible pathway to uncontrolled hyperglycemia, not as a risk factor measured in this cohort. The copy does not establish alcohol or substance use as an associated factor, and its behavioral-health finding is specifically depression. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [195] Gibb, 2016, Risk of death following admission to a UK hospital with diabetic ketoacidosis, Diabetologia sourcePartly supported

  The Introduction and Discussion link DKA admissions or recurrence with social deprivation, high HbA1c, reduced adherence to insulin therapy, younger age at diabetes diagnosis, and mental health issues. The paper addresses DKA rather than all hyperglycemic crises, and it does not establish prior hypoglycemic crises, other chronic conditions, insulin rationing, or SGLT2 inhibitor use as risk factors. Its Results table examines complications and excess alcohol intake in relation to death after DKA, not the risk of a crisis. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [196] Randall, 2011, Recurrent diabetic ketoacidosis in inner-city minority patients: behavioral, socioeconomic, and psychosocial factors, Diabetes Care sourcePartly supported

  The Results (page not provided) link recurrent DKA in inner-city minority patients with substance abuse, homelessness, depression, and younger age at diabetes onset; they also identify insulin discontinuation, including stretching the supply, as a precipitating cause. This supports several listed factors, but the paper does not establish younger age at crisis, prior hypoglycemic crises, other diabetes complications, high A1C, or SGLT2 inhibitor use as risk factors. Its findings concern DKA in this population, not hyperglycemic crises generally. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

Some hemoglobin variants can interfere with some A1C assays; however, most assays in use in the U.S. are accurate in individuals who are heterozygous for the most common variants.

“Some hemoglobin variants can interfere with some A1C assays; however, most assays in use in the U.S. are accurate in individuals who are heterozygous for the most common variants (7).”

• cites [7] National Glycohemoglobin Standardization Program. HbA1c assay interferences. HbA1c methods: effects of hemoglobin variants (HbC, HbS, HbE and HbD traits) and elevated fetal hemoglobin (HbF). 2022. Accessed 14 August 2025. Available from https://ngsp.org/interf.aspNot checked yet

  Not checked in the free run.

May combine two claims.

A1C does not provide a measure of glycemic variability, real-time glucose levels, or hypoglycemia.

“A1C does not provide a measure of glycemic variability, real-time glucose levels, or hypoglycemia.”

Probably not a substantial claim: may not pass S4 (based).

The A1C test is an indirect measure of average glycemia.

“The A1C test is an indirect measure of average glycemia.”

May combine two claims.

Discordant results between A1C and BGM or CGM can occur due to high glycemic variability, inaccurate BGM or CGM measurement, or inaccurate A1C due to factors affecting hemoglobin or red blood cells.

“Discordant results between A1C and BGM or CGM can occur due to high glycemic variability, inaccurate BGM or CGM measurement, or inaccurate A1C due to the factors discussed above.”

May combine two claims.

The Kumamoto study and UK Prospective Diabetes Study (UKPDS) examined the effects of intensive glycemic control among people with short-duration type 2 diabetes, although glycemic lowering in these studies was not intensive by current standards.

“The Kumamoto study (46) and UK Prospective Diabetes Study (UKPDS) (47,48) examined the effects of “intensive glycemic control” among people with shortduration type 2 diabetes, although glycemic lowering in these studies was not intensive by current standards (mean A1C was 7.1% vs. 9.4% in Kumamoto and 7.0% vs. 7.9% in UKPDS).”

• cites [46] Ohkubo, 1995, Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Res Clin Pract sourceNot checked — no full text of the source
• cites [47] UK Prospective Diabetes Study (UKPDS) Group, 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet sourceNot checked — no full text of the source
• cites [48] UK Prospective Diabetes Study (UKPDS) Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet sourceNot checked — no full text of the source

May combine two claims.

Published data from two retrospective studies suggest a strong correlation between TIR and A1C, with a goal of >70% TIR aligning with an A1C of approximately 7% (approximately 53 mmol/mol).

“Published data from two retrospective studies suggest a strong correlation between TIR and A1C, with a goal of >70% TIR aligning with an A1C of ∼7% (∼53 mmol/mol) (25,28).”

• cites [25] Beck, 2019, The relationships between time in range, hyperglycemia metrics, and HbA1c, J Diabetes Sci Technol sourceNot checked — no full text of the source
• cites [28] Vigersky, 2019, The relationship of hemoglobin A1C to time-in-range in patients with diabetes, Diabetes Technol Ther sourceNot checked — no full text of the source

May combine two claims.

Fructosamine and glycated albumin are highly correlated in people with diabetes, and the performance of modern assays is typically excellent.

“Fructosamine and glycated albumin are highly correlated in people with diabetes, and the performance of modern assays is typically excellent.”

May combine two claims.

Both BGM and CGM allow people with diabetes to evaluate individual responses to therapy and assess whether glycemic goals are being safely achieved.

“Both approaches to glucose monitoring allow people with diabetes to evaluate individual responses to therapy and assess whether glycemic goals are being safely achieved.”

May combine two claims.

The comparability of A1C and mean glucose from CGM systems depends on the number of days of CGM wear, timing of the A1C measurement relative to the CGM wear period, calibration and accuracy of both the glucose meter and the CGM system, the lag time between interstitial glucose and venous glucose, and any factors that affect A1C or red blood cell turnover.

“The comparability of A1C and mean glucose from CGM systems will depend on the number of days of CGM wear, timing of the A1C measurement relative to the CGM wear period, calibration and accuracy of both the glucose meter and the CGM system, the lag time between interstitial glucose and venous glucose (which varies among individuals and within individuals based on physical activity and health status”

Probably not a substantial claim: may not pass S3 (load-bearing).

Fructosamine reflects total glycated serum proteins, mostly albumin.

“Fructosamine reflects total glycated serum proteins (mostly albumin).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Glycated albumin assays reflect the proportion of total albumin that is glycated.

“Glycated albumin assays reflect the proportion of total albumin that is glycated.”

May combine two claims.

TBR (<70 and <54 mg/dL) and TAR (>180 mg/dL) are useful parameters for insulin dose adjustments, reevaluation of the treatment plan, and real-time detection, prevention, and treatment of hypoglycemia and significant hyperglycemia.

“TBR (<70 and <54 mg/dL [<3.9 and <3.0 mmol/L]) and TAR (>180 mg/dL [>10.0 mmol/L]) are useful parameters for insulin dose adjustments, reevaluation of the treatment plan, and real-time detection, prevention, and treatment of hypoglycemia and significant hyperglycemia.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

In recent years, CGM has become a standard method for glucose monitoring for most people with type 1 diabetes and people with type 2 diabetes treated with insulin.

“In recent years, CGM has become a standard method for glucose monitoring for most people with type 1 diabetes and people with type 2 diabetes treated with insulin.”

Probably not a substantial claim: may not pass S3 (load-bearing).

It is unclear how generalizable these estimates are to mean glucose measurements obtained using modern and generally more accurate CGM systems.

“It is unclear how generalizable these estimates are to mean glucose measurements obtained using modern and generally more accurate CGM systems.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Use of CGM in type 2 diabetes, as well as in several other forms of diabetes, is growing, especially in people who are taking insulin.

“Use of CGM in type 2 diabetes (as well as in several other forms of diabetes) is growing, especially in people who are taking insulin.”

May combine two claims.

There have been few clinical trials, and the evidence base supporting the use of fructosamine or glycated albumin to monitor glycemic status is much weaker than that for A1C.

“However, there have been few clinical trials, and the evidence base supporting the use of these biomarkers to monitor glycemic status is much weaker than that for A1C.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Caveats in interpretation of Table 6.1 include that these data are from a single study published in 2008.

“Caveats in interpretation of Table 6.1 include that these data are from a single study published in 2008.”

May combine two claims.

These landmark studies were conducted prior to the approval of GLP-1 RAs, dual GIP and GLP-1 RA, and SGLT2 inhibitors, and intensive glucose lowering was achieved predominantly through greater use of insulin and other medications.

“Importantly, these landmark studies were conducted prior to the approval of GLP-1 RAs, dual GIP and GLP-1 RA, and SGLT2 inhibitors, and intensive glucose lowering was achieved predominantly through greater use of insulin and other medications.”

May combine two claims.

In the epidemiological follow-up of ACCORD in ACCORDION, the excess increase in total mortality that was seen during 3.5 years of intensive treatment was reduced by returning to conventional management, and therefore there was no difference in total mortality after a total of 9 years of follow-up.

“In the epidemiological follow-up of ACCORD in the Action to Control Cardiovascular Risk in Diabetes Follow-On Study (ACCORDION), the excess increase in total mortality that was seen during 3.5 years of intensive treatment was reduced by returning to conventional management, and therefore there was no difference in total mortality after a total of 9 years of follow-up (62).”

• cites [62] ACCORD Study Group, 2016, Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes, Diabetes Care sourceNot checked — no full text of the source

May combine two claims.

No significant reduction in composite cardiovascular disease events was demonstrated at the end of the intervention in any of these studies, and ACCORD was stopped prematurely at 3.5 years because of an increase in total mortality, particularly sudden cardiovascular disease deaths.

“No significant reduction in composite CVD events was demonstrated at the end of the intervention in any of these studies, and ACCORD was stopped prematurely at 3.5 years because of an increase in total mortality, particularly sudden CVD deaths.”

May combine two claims.

The UKPDS post-trial 20-year observational follow-up has shown reductions in myocardial infarctions and total mortality both in the group of individuals with overweight treated with metformin and in the group previously treated intensively with sulfonylureas or insulin.

“The UKPDS post-trial 20-year observational follow-up has shown reductions in myocardial infarctions and total mortality both in the group of individuals with overweight treated with metformin and in the group previously treated intensively with sulfonylureas or insulin (49).”

• cites [49] Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source

May combine two claims.

ACCORD, ADVANCE, and VADT were conducted in relatively older participants with a longer duration of diabetes (mean duration 8-11 years) and either cardiovascular disease or multiple cardiovascular risk factors.

“ACCORD, ADVANCE, and VADT were conducted in relatively older participants with a longer duration of diabetes (mean duration 8-11 years) and either CVD or multiple cardiovascular risk factors.”

May combine two claims.

The Kumamoto and UKPDS trials found lower rates of microvascular complications in the intervention arms, with long-term follow-up of the UKPDS cohorts showing enduring effects on most microvascular complications.

“These trials found lower rates of microvascular complications in the intervention arms, with long-term follow-up of the UKPDS cohorts showing enduring effects on most microvascular complications (49).”

• cites [49] Holman, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

CGM use was not as common when the DCCT and UKPDS trials were conducted and automated insulin delivery systems were not available; these have been shown to improve glucose levels without increasing hypoglycemia.

“Moreover, CGM use was not as common when the DCCT and UKPDS trials were conducted and automated insulin delivery systems were not available; these have been shown to improve glucose levels without increasing hypoglycemia.”

May combine two claims.

These landmark studies in individuals with type 2 diabetes did not include GLP-1 RAs, dual GIP and GLP-1 RA, and SGLT2 inhibitors, which are highly beneficial in subgroups like those included in the trials, including individuals with established cardiovascular disease and those at high risk for cardiovascular and kidney complications.

“Importantly, these landmark studies in individuals with type 2 diabetes did not include GLP-1 RAs, dual GIP and GLP-1 RA, and SGLT2 inhibitors, which are highly beneficial in subgroups like those included in the trials (i.e., individuals with established CVD and those at high risk for cardiovascular and kidney complications).”

May combine two claims.

Collectively, results of these studies suggest that long-term intensive glycemic management may reduce cardiovascular disease events, particularly myocardial infarctions, with heterogeneity of results likely driven by differences in study treatments and populations.

“Collectively, results of these studies suggest that longterm intensive glycemic management may reduce CVD events, particularly myocardial infarctions, with heterogeneity of results likely driven by differences in study treatments and populations.”

May combine two claims.

Serious concerns with the intensive glycemic treatment plan used in ACCORD included the rapid escalation of therapies, the early use of large doses of insulin, substantial weight gain, and frequent hypoglycemia.

“Serious concerns with the intensive glycemic treatment plan used in ACCORD included the rapid escalation of therapies, the early use of large doses of insulin, substantial weight gain, and frequent hypoglycemia.”

May combine two claims.

Several glucose-lowering medication classes, notably metformin, GLP-1 receptor agonists, dual GIP and GLP-1 RA, SGLT2 inhibitors, and dipeptidyl peptidase 4 inhibitors, are unlikely to cause hypoglycemia, making it possible for many individuals to achieve lower glycemic goals with a low risk for hypoglycemia.

“Several glucoselowering medication classes-notably, metformin, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), dual GIP and GLP-1 RA, dual GIP and GLP-1 RA, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and dipeptidyl peptidase 4 inhibitors-are unlikely to cause hypoglycemia, making it possible for many individuals to achieve lower glycemic goals with a low risk for hypoglycemia (see s”

Probably not a substantial claim: may not pass S3 (load-bearing).

Symptoms of hypoglycemia include, but are not limited to, shakiness, irritability, confusion, tachycardia, sweating, and hunger.

“Symptoms of hypoglycemia include, but are not limited to, shakiness, irritability, confusion, tachycardia, sweating, and hunger (72).”

• cites [72] Hepburn, 1994, Structural equation modeling of symptoms, awareness and fear of hypoglycemia, and personality in patients with insulin-treated diabetes, Diabetes Care sourceNot checked — no full text of the source

Classified as probably not a substantial claim.

Because many people with diabetes demonstrate impaired counterregulatory responses to hypoglycemia and/or experience impaired hypoglycemia awareness, a measured glucose level <70 mg/dL (<3.9 mmol/L) is considered clinically important, regardless of symptoms.

“Because many people with diabetes demonstrate impaired counterregulatory responses to hypoglycemia and/or experience impaired hypoglycemia awareness, a measured glucose level <70 mg/dL (<3.9 mmol/L) is considered clinically important, regardless of symptoms.”

May combine two claims.

Individuals with impaired hypoglycemia awareness may experience confusion as the first sign of hypoglycemia, which can create fear of hypoglycemia and severely impact quality of life.

“Individuals with impaired hypoglycemia awareness may experience confusion as the first sign of hypoglycemia, which can create fear of hypoglycemia and severely impact quality of life (109).”

• cites [109] Wild, 2007, A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education, Patient Educ Couns sourceNot checked — no full text of the source

May combine two claims.

Hypoglycemia may also cause substantial anxiety that can reduce the quality of life of individuals with diabetes and their caregivers and may contribute to problems with diabetes self-management and treatment.

“Hypoglycemia may also cause substantial anxiety that can reduce the quality of life of individuals with diabetes and their caregivers and may contribute to problems with diabetes selfmanagement and treatment (80)(81)(82).”

• cites [80] Rossi, 2019, Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study, Nutr Metab Cardiovasc Dis sourceNot checked — no full text of the source
• cites [81] McCoy, 2013, Self-report of hypoglycemia and health-related quality of life in patients with type 1 and type 2 diabetes, Endocr Pract sourceNot checked — no full text of the source
• cites [82] Leiter, 2014, Dosing irregularities and self-treated hypoglycemia in type 2 diabetes: results from the Canadian cohort of an international survey of patients and healthcare professionals, Can J Diabetes sourceNot checked — no full text of the source

May combine two claims.

Validated questionnaires for assessing impaired hypoglycemia awareness include the single-question Pedersen-Bjergaard and Gold tools; the Clarke and HypoA-Q tools are longer questionnaires that evaluate multiple domains of impaired hypoglycemia awareness.

“Validated questionnaires for assessing impaired hypoglycemia awareness include the single-question Pedersen-Bjergaard (111) and Gold (112) tools; the Clarke (113) and HypoA-Q (114) tools are longer questionnaires that evaluate multiple domains of impaired hypoglycemia awareness.”

• cites [111] Pedersen-Bjergaard, 2022, The updated Pedersen-Bjergaard method for assessment of awareness of hypoglycaemia in type 1 diabetes, Dan Med JNot checked yet

  Not checked in the free run.

• cites [112] Gold, 1994, Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia, Diabetes Care sourceNot checked — no full text of the source
• cites [113] Clarke, 1995, Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms, Diabetes Care sourceNot checked — no full text of the source
• cites [114] Speight, 2016, Characterizing problematic hypoglycaemia: iterative design and preliminary psychometric validation of the Hypoglycaemia Awareness Questionnaire (HypoA-Q), Diabet Med sourceNot checked — no full text of the source

May combine two claims.

Level 1 and level 2 hypoglycemia can be ascertained from individual self-report and are strong risk factors for subsequent level 3 hypoglycemia.

“Level 1 and level 2 hypoglycemia can be ascertained from individual self-report (93) and are strong risk factors for subsequent level 3 hypoglycemia.”

• cites [93] Au, 2022, Real-world incidence and risk factors for daytime and nocturnal non-severe hypoglycemia in adults with type 2 diabetes mellitus on insulin and/or secretagogues (InHypo-DM study, Canada), Can J Diabetes sourceNot checked — no full text of the source

May combine two claims.

Fear of hypoglycemia and impaired hypoglycemia awareness often co-occur, so interventions aimed at treating one often benefit both.

“Fear of hypoglycemia and impaired hypoglycemia awareness often co-occur, so interventions aimed at treating one often benefit both (154).”

• cites [154] Yeoh, 2015, Interventions that restore awareness of hypoglycemia in adults with type 1 diabetes: a systematic review and meta-analysis, Diabetes Care sourceNot checked — no full text of the source

May combine two claims.

For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental.

“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”

• cites [127] Hering, 2016, Phase 3 trial of transplantation of human islets in type 1 diabetes complicated by severe hypoglycemia, Diabetes Care sourceNot checked — no full text of the source
• cites [128] Boggi, 2022, Treating type 1 diabetes by pancreas transplant alone: a cohort study on actual long-term (10 Years) efficacy and safety, Transplantation sourceNot checked — no full text of the source

May combine two claims.

Structured education for hypoglycemia prevention and treatment is critical and has been shown to improve hypoglycemia outcomes.

“Structured education for hypoglycemia prevention and treatment is critical and has been shown to improve hypoglycemia outcomes (146,147).”

• cites [146] Powers, 2020, Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care sourceNot checked — no full text of the source
• cites [147] LaManna, 2019, Diabetes education impact on hypoglycemia outcomes: a systematic review of evidence and gaps in the literature, Diabetes Educ sourceNot checked — no full text of the source

May combine two claims.

Both DKA and HHS impart a substantial risk of subsequent morbidity and mortality and high associated health care costs.

“Both DKA and HHS impart a substantial risk of subsequent morbidity and mortality and high associated health care costs (165).”

• cites [165] Desai, 2018, Health care utilization and burden of diabetic ketoacidosis in the U.S. over the past decade: a nationwide analysis, Diabetes Care sourceNot checked — no full text of the source